Today's Stock News: Latest Updates on Public Companies

Big pharma and biotech: late-stage wins reshape pipelines

Bristol Myers Squibb (BMY) reported positive Phase 3 results from the SUCCESSOR-2 study of oral mezigdomide in relapsed or refractory multiple myeloma — a data beat that could meaningfully lift expectations for a late-stage oncology franchise and affect valuation assumptions for the company and peers.

Pfizer (PFE) said its Phase 2 study of a trispecific antibody showed benefit in moderate-to-severe atopic dermatitis. For investors, positive mid-stage dermatology data can be an early signal of commercial potential and partnership interest.

Xenon (XENE) announced positive topline Phase 3 results for azetukalner in focal onset seizures, a pivotal readout that sharply reduces binary risk and could accelerate regulatory timelines.

IDEAYA Biosciences (IDYA) hit a milestone with first-patient-in for IDE892, a PRMT5 inhibitor targeting MTAP-deleted tumors — a technical win that expands its precision-oncology pipeline and keeps the stock sensitive to early clinical readouts.

Dianthus Therapeutics (DNTH) announced a go decision to start a Phase 3 CAPTIVATE CIDP trial and released Q4/FY2025 results, a development that moves a mid‑stage neurology program into a pivotal, investor‑relevant phase and reduces program uncertainty.

ImmunityBio (IBRX) said it has resubmitted a supplemental BLA for ANKTIVA® plus BCG in BCG‑unresponsive NMIBC with papillary disease following FDA review of additional data — a regulatory step that could re-open approval and commercial pathways for a previously contested program.

Trevi Therapeutics (TRVI) completed an end-of-Phase 2 meeting with the FDA for its idiopathic pulmonary fibrosis‑related chronic cough program, gaining alignment on a development plan — a de‑risking event that clarifies requirements for pivotal testing and market entry.

Biotech financings, readouts and commercialization updates

ARS Pharmaceuticals (SPRY) reported Q4 and full-year 2025 results and updated on neffy® commercialization — useful evidence of early uptake for a commercial-stage specialty product.

Precision BioSciences (DTIL) received FDA Fast Track for PBGENE‑DMD and announced a DMD investor event, an important regulatory and investor‑relations milestone for gene‑editing programs targeting Duchenne muscular dystrophy.

Abeona Therapeutics (ABEO) provided a business update highlighting momentum in the ZEVASKYN® commercial launch, a signal that early commercial execution could start shaping revenue and adoption expectations.

Medicus Pharma (MDCX) released an analysis of positive Phase 2 SkinJect™ data, keeping investor focus on potential next steps for skin‑targeted delivery technology.

CorBus Pharmaceuticals (CRBP) posted Q4 and 2025 results and a corporate update, items investors will weigh against cash runway and program timelines.

Semiconductors & AI infrastructure: production and orders signal demand

STMicroelectronics (STM) said it has entered high-volume production of a silicon photonics platform built for AI infrastructure. That move is timely as data-center interconnects become a bottleneck for large-scale AI deployments and could lift expectations for STM's growth trajectory.

Applied Optoelectronics / AOI (AAOI) reported it received a first volume order of 1.6T data-center transceivers from a major hyperscaler. This is a concrete validation of product-market fit in a high-growth segment and a near-term revenue catalyst.

Deals and M&A: strategic acquisitions and partnerships

Agilent Technologies (A) agreed to acquire Biocare Medical, expanding Agilent’s footprint in clinical and research pathology. For investors, the deal underlines the company's push into recurring-revenue diagnostics and potential margin uplift from platform synergies.

Tilray Brands (TLRY) closed a strategic step in consumer expansion by acquiring BrewDog Australia, bolstering its beverage and consumer-products distribution in Asia‑Pacific.

Woodward (WWD) announced an agreement to acquire Valve Research & Manufacturing, strengthening its control-systems and flow-control offerings in aerospace and industrial markets.

Calisa Acquisition (ALIS) said it will merge with GoodVision AI, a SPAC tie-up that puts an AI‑enabled vision company on a path to public markets — worth watching for AI investors focused on computer vision monetization.

Capital moves and shareholder actions

United Therapeutics (UTHR) unveiled a sizable capital return program: a $2 billion stock repurchase authorization plus a $1.5 billion accelerated share repurchase program, per its statement. That scale of buyback typically tightens supply and supports EPS, and it signals management's confidence in cash generation.

Cannae Holdings (CNNE) announced an increase in its share repurchase authorization, expanding its commitment to returning capital and potentially boosting per‑share metrics.

Korro (KRRO) closed an oversubscribed $85 million private placement, shoring up funding for commercialization and limiting near‑term dilution.

Relmada Therapeutics (RLMD) completed an oversubscribed $160 million private placement, reducing near‑term funding risk for its pipeline.

Real estate and property moves

Alexander’s (ALX) plans to sell Rego Park I for net proceeds of $202 million, a sizable liquidity event that could be redeployed into higher-return assets or reduce leverage.

SL Green (SLG) reached 100% leased at One Madison Avenue and projects record first‑quarter office leasing across its portfolio — a positive signal for office REIT leasing momentum in prime Manhattan assets.

AMTD Digital (HKD) disclosed that its subsidiary TGE completed the acquisition of the New York Tribeca Hotel for $69 million, a hospitality purchase with local strategic implications.

Energy, resources and industrials

VAALCO Energy (EGY) provided an operational update on offshore Gabon drilling — single-well outcomes that can swing small‑cap E&P valuations.

Genesis Energy (GEL) extended its revolving credit facility and opportunistically repurchased $110 million of Series A convertible preferred units, per its release, strengthening liquidity and lowering conversion overhang.

Borr Drilling (BORR) issued an operational update on Arabian Gulf operations — relevant for dayrate and utilization expectations in offshore services.

Notable product, commercial and tech updates

Himax (HIMX) plans to showcase WiseEye AIoT and automotive display ICs at Embedded World 2026, highlighting ongoing commercialization of automotive and edge‑AI silicon.

Vision Marine (VMAR) introduced a 6‑year limited powertrain warranty for its E‑Motion 180E product, a consumer‑facing move that could ease adoption friction for electric marine craft.

Teletrac Navman (VNT) enhanced its TN360 ACM platform with new financial and asset‑management features, per the update, which may lift retention and monetization in fleet software.

FuelCell Energy (FCEL) posted strong Q1’26 revenue growth versus a year earlier and highlighted advances in its data‑center power strategy — a sign its clean‑power solutions could tap emerging on‑site backup and microgrid demand.

Amazon (AMZN) expanded access to Eli Lilly’s Zepbound KwikPen on Amazon Pharmacy, broadening distribution for a high‑profile weight‑management drug and underscoring Amazon's growing role in pharmacy and healthcare logistics.

Markets, platforms and tokenization

Nasdaq (NDAQ) plans to launch an equity token design, aiming to put issuers at the center of tokenization. For market structure watchers, this is a notable step toward mainstreaming digital securities and could create new issuance and liquidity pathways.

Retail, consumer and activist activity

Starboard delivered a letter to Lamb Weston (LW), a development that can trigger governance scrutiny and potentially strategic review or capital‑allocation shifts at the frozen‑foods name.

Signet Jewelers (SIG) released preliminary Q4 fiscal 2026 results, a cue investors will parse for consumer demand trends and margin trajectory across jewelry retail.

Deal flow and collaborations to watch

Rapport Therapeutics (RAPP) and Tenacia Biotechnology revealed a strategic collaboration to develop RAP‑219 in Greater China — a regional licensing play that can speed local development and commercialization.

NewcelX (ELDN) struck a collaboration with Eledon Pharmaceuticals on NCEL‑101 for type 1 diabetes, underscoring ongoing partnership activity in specialty biologics.

• Note: This article highlights the day's most market‑moving items, selected for investor impact across clinical readouts, major capital actions, strategic M&A, AI/data‑center infrastructure, and notable commercial or regulatory milestones.